Bio-Techne (TECH) Current Deferred Revenue (2014 - 2026)

Bio-Techne's Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $40.7 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 26.13% year-over-year to $40.7 million in Q1 2026; TTM through Mar 2026 was $40.7 million, a 26.13% increase from a year earlier, with the FY2025 full-year figure at $32.6 million, up 7.85% from the prior year.
• Current Deferred Revenue advanced to $40.7 million in Q1 2026 per TECH's latest filing, from $31.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $40.7 million in Q1 2026 and bottomed at $21.8 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $30.1 million (2023), against an average of $28.5 million.
• Biggest YoY gain for Current Deferred Revenue was 38.0% in 2023; the steepest drop was 3.53% in 2023.
• Year by year, Current Deferred Revenue stood at $21.8 million in 2022, then soared by 38.0% to $30.1 million in 2023, then increased by 1.0% to $30.4 million in 2024, then increased by 2.07% to $31.0 million in 2025, then jumped by 31.16% to $40.7 million in 2026.
• Per Business Quant, the three latest TECH Current Deferred Revenue figures stand at $40.7 million (Q1 2026), $31.0 million (Q4 2025), and $30.4 million (Q3 2025).